ArticleAntimicrobial agents and chemotherapy2012
Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Detection of Candida Species in Genitourinary Tract among Immunocompromised Patients Attending Rural Teaching Hospital.Annals of African medicine · 2026Article
- The Antimicrobial Resistance ofJournal of fungi (Basel, Switzerland) · 2025Article
- The prevalence, patterns, and antifungal drug resistance of bloodstream infection-causing fungi in Sichuan Province, China (2019-2023): a retrospective observational study using national monitoring data.Frontiers in microbiology · 2025Article
- Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait.Scientific reports · 2020Article
- Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.Antimicrobial agents and chemotherapy · 2020Review
- Article
- Changing Epidemiology of Invasive Candidiasis in Children during a 10-Year Period.Journal of fungi (Basel, Switzerland) · 2019Article
- Treatment of Invasive Candidiasis: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2018Review
- Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside.Future microbiology · 2018Review
- Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance.Journal of visualized experiments : JoVE · 2017Article
- Etest and Sensititre YeastOne Susceptibility Testing of Echinocandins against Candida Species from a Single Center in Austria.Antimicrobial agents and chemotherapy · 2017Article
- Revisiting Species Distribution and Antifungal Susceptibility of Candida Bloodstream Isolates from Latin American Medical Centers.Journal of fungi (Basel, Switzerland) · 2017Review
- Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.Antimicrobial agents and chemotherapy · 2017Article
- Caspofungin MIC Distribution amongst Commonly IsolatedJournal of clinical and diagnostic research : JCDR · 2016Article
- Hot topics in antifungal susceptibility testing: A new drug, a bad bug, sweeping caspofungin testing under the rug, and solving the ECV shrug.Clinical microbiology newsletter · 2016Article
- Two echinocandin-resistant Candida glabrata FKS mutants from South Africa.Medical mycology case reports · 2016Article
- Clinical perspectives on echinocandin resistance among Candida species.Current opinion in infectious diseases · 2015Review
- Evaluation of the "Dip Effect" Phenomenon in Antifungal Susceptibility Testing of Candida spp. against Echinocandins by Use of Gradient Concentration Strips.Journal of clinical microbiology · 2015Article
- Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.Antimicrobial agents and chemotherapy · 2015Article
- In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey.Jundishapur journal of microbiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to evaluate the performance of caspofungin Etest and the recently revised CLSI breakpoints. A total of 497 blood isolates, of which 496 were wild-type isolates, were included. A total of 65/496 susceptible isolates (13.1%) were misclassified as intermediate (I) or resistant (R). Such misclassifications were most commonly observed for Candida krusei (73.1%) and Candida glabrata (33.1%). The revised breakpoints cannot be safely adopted for these two species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.